In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shanghai Pharmaceuticals completes $1.99bn IPO on HKSE

Executive Summary

After months of speculation as to the offering size and price, China's second-largest drug distributor Shanghai Pharmaceuticals Holding Co. Ltd. has netted HKD15.5bn ($1.99bn)--including the overallotment--in an IPO on the Hong Kong Exchange, making it the second-biggest pharmaceutical IPO to date. In the global offer, the company sold approximately 696mm shares--representing over 25% of the company’s enlarged issued share capital--at HKD23.00. The anticipated range was HKD21.80-26.00.
Deal Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies